Nicotinamide reduces the formation of non-melanoma skin cancer
0 Views
administrator
07/10/23
Andrew Martin, MD, Biostatistician at NHMRC Clinical Trials Centre discusses the phase 3 double-blind randomized controlled trial on oral nicotinamide to reduce actinic cancer at the American Society of Clinical Oncology 2015 Annual Meeting.
MDLinx Conference Coverage - 2015 ASCO Annual Meeting: http://www.mdlinx.com/conferen....ce-interview/asco-20
MDLinx: http://www.mdlinx.com/
Smartest Doc & Board Exam Prep: http://www.thesmartestdoc.com/
M3 USA: http://usa.m3.com/
Follow MDLinx:
Facebook - https://www.facebook.com/MDLinx
Twitter - https://twitter.com/MDLinx
Google+ - https://plus.google.com/+Mdlinx/
-
Category
Show more
Facebook Comments
No comments found